JAVELIN PHARMACEUTICALS, INC 4
4 · JAVELIN PHARMACEUTICALS, INC · Filed Jun 8, 2007
Insider Transaction Report
Form 4
Nebgen Georg
Director
Transactions
- Exercise of In-Money
Common Stock
2007-06-01$2.25/sh+65,271$146,860→ 1,370,693 total(indirect: See FN 2.) - Exercise of In-Money
Warrants (right to buy)
2007-06-01−90,284→ 0 total(indirect: See FN 1.)Exercise: $2.25From: 2005-11-07Exp: 2010-11-07→ Common Stock (90,284 underlying) - Exercise of In-Money
Common Stock
2007-06-01$2.25/sh+90,284$203,139→ 1,805,689 total(indirect: See FN 1.) - Exercise of In-Money
Warrants (right to buy)
2007-06-01−65,271→ 0 total(indirect: See FN 2.)Exercise: $2.25From: 2005-11-07Exp: 2010-11-07→ Common Stock (65,271 underlying)
Footnotes (2)
- [F1]The reporting person is a managing member of NGN Capital, LLC, which is the sole general partner of NGN BioMed I, GP, L.P. ("NGN GP") and the managing limited partner of NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG. NGN GP is the sole general partner of NGN Biomed Opportunity I, L.P. The reporting person disclaims beneficial ownership of the securities except to the extent of his indirect pecuniary interest therein. This note shall not be deemed an admission that the reporting person is the beneficial owner of the securities for the purposes of Section 16 or for any other purpose. These securities are beneficially owned by NGN BioMed Opportunity I, L.P.
- [F2]The reporting person is a managing member of NGN Capital, LLC, which is the sole general partner of NGN BioMed I, GP, L.P. ("NGN GP") and the managing limited partner of NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG. NGN GP is the sole general partner of NGN Biomed Opportunity I, L.P. The reporting person disclaims beneficial ownership of the securities except to the extent of his indirect pecuniary interest therein. This note shall not be deemed an admission that the reporting person is the beneficial owner of the securities for the purposes of Section 16 or for any other purpose. These securities are beneficially owned by NGN BioMed Opportunity I GmbH & Co. Beteiligungs KG.